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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.05.005Dengue fever is endemic in many parts of the world but it has not been described as a cause of febrile
neutropenia. We describe here clinical features, laboratory values and outcome in 10 children with acute
lymphoblastic leukemia (ALL) and with dengue fever as a cause of febrile neutropenia. These data are
compared to an age-matched control population of 22 children with proven dengue infection without
ALL. Except for fever in all patients and plethoric face in one patient, typical symptoms of dengue such
as abdominal pain, myalgias, and headaches, were absent. Mean duration of hospital stay was
6.3 ± 2.0 days in ALL patients vs. 5.0 ± 2.0 in controls (p = 0.096). Median platelet count was 13,000/
cmm (range 1000–28,000) in cases vs. 31,500 (range 13,000–150,000) in controls (p = 0.018). Mean time
for recovery for platelet was 6.0 ± 1.3 days in ALL patients vs. 2.5 ± 0.9 days in controls (p < 0.001). All
10 patients survived. In endemic areas, high suspicion of dengue fever should be maintained in children
with ALL and febrile neutropenia although typical symptoms may be lacking. Platelet recovery may be
significantly delayed.Dengue virus (DEN) is a small single-strandedRNA virus comprising four distinct sero-types (DEN-1 to 4). ‘Asian’ genotypes of
DEN-2 and DEN-3 are frequently associated with se-
vere disease accompanying secondary dengue infec-
tions.1 Dengue is quite common in India in both
urban and suburban areas. In 2010, a total of 27,196
cases and 104 deaths were reported in India. Delhi
had the highest number: at 6240 cases and eight
deaths.2
There are multiple reasons for a child to have feb-
rile neutropenia post-chemotherapy but bacterial and
fungal etiologies are usually investigated. It is impor-
tant to describe dengue infection as an etiology of feb-
rile neutropenia in children with ALL as it has not
been previously reported and its clinical course is
not known in this population. Management also dif-
fers with focus on ﬂuid therapy rather than antibiot-
ics. Here we describe clinical proﬁles, courses andHematol Oncol Stem Cell Ther 6(2) Second Quarter 2013outcomes of dengue infection in febrile neutropenic
children with ALL.METHOD
The medical records of all 58 cases of febrile neutro-
penia (Fever > 37.5 C on a single occasion or fever
of 37 C on more than two occasions, 30 mins
apart with Absolute Neutrophil Count of less than
1000/ll) in children with ALL admitted to Sir Ganga
Ram Hospital between July 2010 and December 2010
were retrospectively analyzed.
Diagnosis of dengue infection was performed at
screening with a Dengue NS1 antigen (Panbio,
Australia) and conﬁrmed with an IgM and IgG
capture enzyme-linked immunosorbent assay
(McELISA) (Panbio, Australia). Initially all children
received broad spectrum intravenous antibiotics.
The antibiotics were stopped once the diagnosis of65
Table 1. Clinical profile
No. Phase of Protocol
1 Maintenance
2 Maintenance
3 Day+10 post reind
4 Maintenance
5 Maintenance
6 Just off treatment
7 Day+11 post reind
8 Day+8 post second
intensification
9 Maintenance
10 Maintenance
Hb – Hemoglobin, Plt – Platelet
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dengue was conﬁrmed and blood cultures were
negative. All children diagnosed with dengue hemor-
rhagic fever received appropriate ﬂuid therapy. A total
of 10/58 (16%) consecutive children with ALL and
febrile neutropenia had proven dengue infection. Data
regarding symptomatology, clinical course, laboratory
values and outcome were analyzed. Their laboratory
values were compared with an age-matched control
population of 22 children with proven dengue infec-
tion without underlying ALL. T-test and Mann–
Whitney U-test were applied as these were applicable
for comparison.RESULTS
Ten out of 58 febrile neutropenic ALL patients had
dengue infection. Their clinical proﬁle is described
(Table 1). NS1 antigen was positive in all 10 cases
with a mean of 3.5 days of fever. IgM (McELISA)
was positive in seven patients with a mean of 6.5 days.
In two patients, NS1 antigen was negative initially
and became positive after ﬁve days. Six patients had
dengue fever, two had dengue hemorrhagic fever
(DHF), and two had dengue shock syndrome
(DSS). Except for fever, typical symptoms of dengue
infection such as plethoric face, abdominal pain, myal-
gia, and headache were absent (only one patient had
plethoric face).
Mean duration of hospital stay was 6.3 ± 2.0 days
in ALL patients vs. 5.0 ± 2.0 in controls (p = 0.096).of patients of acute lymphoblastic leukemia with dengue.
Diagnosis Symptoms on
admission
Hb g/dl
(Max)
Lowest
platelet/mm3
Platelet
support
DSS Fever 9.9 13,000 yes
DHF Fever 9.7 1000 yes
uction DSS Fever with
plethoric face
13.7 9000 yes
DF Fever 10.8 14,000 yes
DF Fever 11.2 13,000 yes
DF Fever 17.1 28,000 no
uction DF Fever 8.3 8000 yes
DHF Fever 9.9 9000 yes
DF Fever 10 20,000 No
DF Fever 11.5 15,000 No
s, Req – Requirement, Ng – negative, Ps – Positive.Two patients required ﬂuid replacement at a rate
>10 ml/kg/hr and two at 7 ml/kg/hr. Cases had
median platelet count of 13,000/cmm (range 1000–
28,000) vs. 31,500 (range 13,000–150,000) in con-
trols (p = 0.018). Mean recovery time for platelet
was 6.0 ± 1.3 days in cases vs. 2.5 ± 0.9 days in con-
trols (p < 0.001) (Table 2). One patient also had
blood culture positive for Acinetobacter baumannii.
Eight patients had deranged liver function. All 10
survived.DISCUSSION
Children with ALL are immunocompromised. They
face high risk of sepsis during the neutropenic phase
of post-chemotherapy. Sepsis is a major barrier to im-
prove survival of children with ALL in developing
countries.3 Multiple etiological factors have been men-
tioned for febrile neutropenia, mainly bacterial, viral
and fungal infections. Dengue has rarely been men-
tioned in the literature as a cause for febrile neutrope-
nia in children with ALL. Dengue and other
arboviruses can be associated with bone marrow fail-
ure. It is known that dengue subtype DEN-4 can
reproduce in the progenitor cells of the bone marrow.
Neutropenia and thrombocytopenia are common in
dengue infection due to hypocellular bone marrow
and abnormal megakaryopoesis.4 It is believed that
dengue-induced pancytopenia is a direct consequence
of both peripheral destruction induced by immuneNS1 Ag
positive
Fluid req. ml/
kg/hr
Complications SGOT/
SGPT
Outcome
Day 3 10 Pl. effusion, ascites 306/159 Survived
Day 3 7 none 130/116 Survived
Ng day 2 Ps
day 5
10 Pl. effusion, ascites 235/116 Survived
Day 2 3 None 190/154 Survived
Day 2 3 None 118/102 Survived
Day 3 3 None 46/26 Survived
Day 3 3 None 120/80 Survived
7 Pl. effusion, ascites,
bleeding
324/180 Survived
Day 3 3 None 124/116 Survived
Day 3 3 None Not doneSurvived
Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013
Table 2. Comparison of platelet recovery time, hospital stay, Hb, TLC and lowest platelets
between cases and controls.
Case Control P value
Mean+/S.D
Hospital stay (days) 6.3+/2.0 5.0+/2.0 <0.096a
Platelet recovery (days) 6.0+/1.3 2.5+/ <0.001a
Median and range
Hb 10.4 (8.3–12.1) 12.7 (11.2–15.4) 0.031
TLC 1500 (650–2400) 4600 (2900–8100) <0.001
Lowest platelet count 13000 (1000–16000) 31500 (21000–70000) 0.018
aT test, TLC (Total Leucocytes Count), Hb (Hemoglobin).
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complexes and direct viral injury to the bone
marrow.5
In our patients there was a signiﬁcant difference in
platelet recovery time and lowest TLC between chil-
dren with ALL and controls (p < .001). The possible
explanation could be prior immunocompromised sta-
tus in ALL patients and neutropenia due to chemo-
therapy with superimposed marrow invasion by
dengue virus which leads to marked neutropenia
and thrombocytopenia and/or peripheral immune
destruction of platelets after dengue virus infection.
Reticulocytopenia, lymphocytopenia, thrombocytope-
nia and granulocytopenia appear in this order.6 Our
six patients were in the maintenance phase of chemo-
therapy (daily oral 6-Mercaptopurine and weekly oral
Methotrexate) and one had recently completed treat-
ment. They had signiﬁcant neutropenia and thrombo-
cytopenia which were less likely to be due to oral
maintenance chemotherapy. One patient developed
DHF post intensiﬁcation chemotherapy and another
developed DSS post re-induction chemotherapy.
Both developed severe neutropenia and thrombocyto-
penia along with other complications like bleeding,
pleural effusion and ascites. Systemic symptoms such
as increases in hematocrit, thrombocytopenia, and
hemorrhagic manifestations due to abnormalities of
capillary permeability which characterize DHF, usu-
ally appear during the second episode of dengue infec-
tion in 95% of cases.5 However, the four patients who
developed DHF and DSS had no past history of den-
gue infection. A recent report of dengue infection in
six cancer patients which included one case of ALL
highlighted a mean delay in diagnosis of 10 days.7
Due to early suspicion and timely diagnosis of dengue
infection, all patients in our series received prompt
adequate ﬂuid therapy according to their clinical con-
dition. All 10 patients survived. Prevention of the
mosquito bite is the best strategy to reduce dengue in-
duced febrile neutropenia. We routinely educate par-
ents and patients on how to avoid mosquito bites.Hematol Oncol Stem Cell Ther 6(2) Second Quarter 2013Government also supports this effort through news-
papers, television and radio advertisements on the
prevention of mosquito bites. Prevention can be
achieved by use of mosquito nets, application of mos-
quito repellent, regular insecticidal spray and avoid-
ance of water collection in and around homes to
avoid mosquito breeding.
We recommend high suspicion of dengue fever as
a cause of febrile neutropenia in children with ALL in
endemic areas even in the absence of typical symp-
toms of dengue fever. Platelet recovery may be signif-
icantly delayed.CONFLICT OF INTEREST
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